Allotypic markers of rabbit IgM

Five different allotypic specificities called Ms1 to Ms5 were identified in rabbit sera by agar gel precipitation with the use of antisera developed in the same species. Immunoelectrophoresis and investigation of purified immunoglobulin classes have shown that these allotypes are on IgM molecules. The cellular localization of these allotypes has been studied by immunofluorescence on rabbit plasma cells; numerous double-staining experiments with different antisera have confirmed the presence of these allotypes in IgM synthesizing plasma cells. One allotype, Ms3, has been shown to be strictly limited to the IgM plasma cells containing the b locus allotype As4, while for allotypes Ms4 and Ms5 the expression in plasma cells appeared to be connected with the expression of the a locus allotypes. This last condition also applied to allotype Ms6, an IgM allotype which was demonstrated by the immunofluorescence studies only. The observations performed are consistent with the hypothesis that allotype Ms3 is in fact an allotype of the κ-light chains which is expressed only when these chains are part of an IgM molecule, while allotypes Ms4, Ms5 and Ms6 are true markers of the μ-chain. This hypothesis is also supported by absorption experiments performed with separated heavy and light chains of rabbit IgM.     

Partial sequence of the variable region of IgG light chains of b5 allotype from A B4B5 rabbit.

The partial sequence (positions 29–71) of the variable region of light chains of predominately b5 allotype from the IgG of a single allotype-suppressed rabbit was obtained by traditional sequencing methods on isolated tryptic and chymotryptic peptides. The peptides from this region were isolated in relatively high yields and probably represent a dominant sequence. The framework sequence between positions 35 and 49 (FR 2) is identical to an FR 2 sequence commonly found in light chains from antibodies produced by b4 rabbits as well as murine and human myeloma light chains, with the exception of an interchange of threonine for proline at position 43 or 44. This may be b5 allotype-related since, to date, all the b4 light chains have had proline, and a b9 light chain was found with arginine at position 43. The fact that a dominant sequence could also be found for positions corresponding to the second complementarity determining region (CDR 2, 50–56) in other species, confirms previous observations that this portion of the light chain is not extremely variable in the rabbit.     

Characterization of anti-idiotypic antibodies and their use as probes for determination of shared idiotopes expressed on murine and human IgE anti-rye I antibodies.

This study describes the production and characterization of rabbit anti-idiotypic antibodies (anti-ID Abs) against three idiotypes of three mAbs with different specificities. The anti-ID Abs were rendered idiotype specific by appropriate adsorption. Binding of labelled mAb to homologous anti-ID Ab bound to a polystyrene matrix was completely inhibited when the same mAb was added. In contrast, addition of other mAbs sharing the same isotype and the same light chain but with different specificity did not affect the binding reaction. Each anti-ID Ab inhibited completely and selectively the reaction between the allergen and the homologous mAb idiotype. Labelled rye I binding to a given polystyrene-bound mAb idiotype was completely blocked if the relevant anti-ID Ab was used as an inhibitor. Murine polyclonal anti-rye I antisera inhibited the reaction between all three mAbs and the antigens, as well as the reaction between all three mAb idiotypes and their homologous anti-ID Abs. On another hand, goat polyclonal anti-rye I antisera only inhibited the reaction between the mAbs and the antigens. These results suggest that the anti-ID Abs produced are directed against idiotopes located within the paratopes and such idiotopes are shared by murine monoclonal and polyclonal Abs. Human rye I-specific IgE and murine anti-rye I mAbs could share common idiotopes, since human IgE binding to the antigen was inhibited by the anti-ID Abs. These observations imply structural similarity in the V gene coding for the variable region of the antibody of two different species.     

Establishment of recombinant hybrid-IgG/IgA immunoglobulin specific for Shiga toxin

Shiga toxin 1 produced by enterohaemorrhagic Escherichia coli is an AB(5) toxin that is involved in the life-threatening haemolytic-uraemic syndrome. The B subunits (Stx1B) are cell-binding subunits. We previously established mouse hybridoma cell line producing IgA and IgG monoclonal antibodies (mAbs) against Stx1B. Here, we cloned cDNAs encoding each of the heavy, light and joining (J) chains from the hybridoma cell lines by means of the 5' rapid amplification of cDNA ends (RACE) PCR method. Upon assignment of the variable regions of the heavy and light chains to known germline sequences, we found substantial somatic hypermutation in the complementarity-determining regions in both the IgA and IgG mAbs. We also established a hybrid-IgG/IgA heavy chain having variable regions of the IgG mAb by means of recombinant PCR methods. Upon transient expression of the hybrid-IgG/IgA heavy, IgG-associated light and J chains in COS-1 cells, the translated dimeric hybrid-IgG/IgA bound to immobilized Stx1B, as revealed on ELISA. The production of dimeric hybrid-IgG/IgA was revealed on immunoblot analysis. The dimeric hybrid-IgG/IgA inhibited the binding of digoxigenin-conjugated Stx1B to natural ligands (CD77) displayed on Burkitt's lymphoma cell line Ramos. These results indicate that the replacement of variable regions resulted in the production of more useful recombinant dimeric IgA against Stx1B.     

Characterization of monoclonal immunoglobulin a and g against shiga toxin binding subunits produced by intranasal immunization

Immunoglobulin A (IgA) is considered to play a major role in protection of the mucosal surface. However, its immunological and biological properties have not been extensively studied because the production of IgA class monoclonal antibodies (mAbs) is difficult. We compared the properties of IgA and IgG mAbs against Shiga toxin B subunits (Stx1B). These mAbs were secreted from hybridomas that had been produced from mice after intranasal immunization with recombinant Stx1B and cholera toxin. The dose response curves for the binding of the IgA (clone G2G7) and IgG (clone D11C6) mAbs to immobilized Stx1B were similar, as revealed on ELISA. The majority of the IgA mAb formed dimers while the IgG mAb was monomeric, as judged by immunoblot analysis. The IgG mAb completely inhibited the binding of Stx1B to Burkitt's lymphoma cell line Ramos, while the inhibition by the IgA mAb was only partial. The IgG mAb was able to neutralize the cytotoxicity of Stx1 holotoxin towards Vero cells, whereas the IgA mAb was not. The binding affinity of each binding site was compared by means of surface plasmon resonance analysis involving a capture method, with which the binding of soluble Stx1B to immobilized mAb was detected. The association rate was similar but the dissociation rate was twofold faster in the case of the IgA mAb, resulting in twofold higher affinity of the IgG mAb. These results suggest that one can obtain high affinity IgA mAb but toxin neutralization is another challenge as to therapeutic antibodies of the IgA class.     

Shigella-: Rabbit Gamma-Globulin Allotypes as Genetic Markers for the Source of Antibody Produced in Recipients of* • Incubated Lymph Node Cells*

Rabbits homozygous for each of an allelic pair of allotypes of γ globulin (A4 and A5) were used as donors and recipients of transferred antigen-incubated lymph node cells, the cells of donors of one allotype being in each case transferred to recipients of the other. When agglutinins to Shigella (the source of the antigen with which the lymph node cells were incubated) appeared in the sera of the recipient animals, the allotype of the agglutinin was determined by adsorbing it to Shigella on a glass slide, then treating the preparations with fluorescein-conjugated rabbit anti-A5-γ-globulin and anti-A4-γ-globulin antisera, respectively. In each case the reactions of the recipients' sera were positive for γ globulin of the donors' allotype but not of their own. Positive reactions were given only by sera above a certain range of agglutinin titre.

After sufficient decline of the agglutinin level in the sera of the recipients, these animals were actively immunized with Shigella. The agglutinins that now appeared in these rabbits gave positive reactions with the fluorescent antibody against their own allotype.

These data indicated that in moderately X-irradiated rabbits given antigen-incubated rabbit lymph node cells, the antibody that subsequently appears in the recipient's serum has been synthesized by the donor's cells.

These experiments also illustrate the use of allotypes as genetic markers in lymph node cell transfer experiments.

     

A glycolipid-specific monoclonal antibody modulates Fcε receptor stimulation of mast cells

In an effort to identify membrane components participating in coupling stimulus to secretion in mast cells, monoclonal antibodies were produced from spleen cells of mice immunized with plasma membranes isolated from rat mast cells of the RBL-2H3 line. The resultant mAbs were screened by their capacity to modulate the secretory response of these cells to crosslinking of their type 1 Fcε receptor (Fc_εRI). Following this scheme, we obtained a hybridoma designated B17, which secretes an IgM-class mAb (B17) that binds to and modulates secretion from RBL-2H3 cells. By immunoblotting, B17 was shown to bind to a membrane component of low molecular weight, later identified as a glycolipid. While B17 partially inhibits IgE binding to RBL-2H3 cells, no noticeable inhibition of B17 binding by IgE was observed. mAb B17 does not cause any secretory response on its own, and its modulatory effect on Fc_εRI-mediated secretion is bimodal: it either enhances or inhibits secretion, depending on the B17 dose and also on the nature and dose of the agent used for crosslinking the Fc_εRI. When secretion was induced by IgE and suboptimal or optimal doses of multivalent antigen, B17 (2–80 nM) caused an increase in secretion. However, higher doses of B17 (>150nM) inhibited secretion. Secretion induced by supraoptimal doses of antigen, or by the Fc_εRI-specific mAb F4 was inhibited by B17 at all the dose range tested (2–200 nM). In contrast, B17 had no effect on secretion induced by Ca²⁺ ionophores. These results demonstrate that Fc_εRI function is modulated by a mAb binding to a membrane glycolipid.     

Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b

The alternative pathway (AP) of the complement system plays an important role in tissue damage and inflammation associated with certain autoimmune diseases and with ischemia-reperfusion injury. Selective inhibition of the AP could prevent such pathologies while allowing the classical and lectin pathways of complement activation to continue to provide protection. Here we present data describing selective inhibition of the AP of complement by anti-C3b/iC3b monoclonal antibody (mAb) 3E7, and by a chimeric, "deimmunized" form of this mAb, H17, which contains the human IgG1 Fc region and was further modified by substitution of amino acids in order to remove T cell epitopes. Both mAbs block AP-mediated deposition of C3b onto zymosan or Sepharose 4B, and they also inhibit AP-promoted lysis of rabbit erythrocytes. MAbs 3E7 and H17 also successfully compete with both factors B and H for binding to C3b-opsonized substrates, and the ability of both mAbs to inhibit the AP is blocked by pre-incubation with two different sources of C3(H2O). Kinetic measurements demonstrate that mAb 3E7 effectively stops progression of C3b deposition after AP activation is initiated. Our results therefore suggest that these mAbs block activation of the AP by binding to both C3(H2O) and to C3b, and thus prevent binding and activation of factor B. Based on these and other observations, mAb H17 may find future use in therapeutic applications focused on selective inhibition of the AP.     

Glomerular lesions induced in the rabbit by physicochemically altered homologous IgG.

Immunization of rabbits with physicochemically altered homologous or even autologous IgG induces formation of antibodies combining with IgG of rabbit and of foreign species. Cardiac but not renal lesions were reported in such animals. This study examined the nephritogenic potential of the immune response to cationized or heat-aggregated homologous IgG of b9 or b4 allotype in rabbits of the b4 allotype. Rabbits injected with either b9 or b4 cationized IgG produced antibodies reactive with rabbit and human IgG and with histones; they also developed abnormal glomerular deposits of IgG b4 and C3 corresponding to alterations of the glomerular basement membranes (GBM). Rabbits injected with either b9 or b4 aggregated IgG developed antibodies reactive with rabbit and human IgG and abnormal glomerular deposits of IgG b4 and C3 in the GBM and in the mesangium with subendothelial and mesangial electron-dense deposits. Some rabbits in both groups had proliferative and exudative glomerulonephritis and proteinuria. The results showed that immunization of rabbits with physicochemically altered homologous IgG induces an immune response to rabbit and human IgG and to histones as well as glomerular deposits of autologous IgG and C3 and other glomerular lesions.     

B 96, a seventh allele at the rabbit kappa chain b locus

A previously undetected allotypic specificity, A96, was observed in the wild rabbit population of Zembra (Tunisia). The A96 allotype is inherited as a b allotype, and its antigenic determinants are located on the kappa light chains of immunoglobulins. Although cross-reacting with b6, the A96 allotype carries its own allotypic determinants, and is therefore distinct form the known allotypes of the b series (b4, b5, b6, b9, b4var and b95). The data indicate that A96 is encoded by an allele at the b locus, tentatively designated b 96.     

Immunology: Diversity of the blocking effects of antisperm antibodies on fertilization in human and mouse

The blocking effects of complement-dependent sperm immobilizingantibodies in the sera of infertile women and monoclonal antispermantibodies against humans and mice on fertilization were investigated.The hemizona assay (HZA) and sperm penetration assay (SPA) wereused to study the inhibitory effects of sera from 22 infertilepatients positive for sperm immobilizing antibodies. Use ofthese tests allowed us to differentiate whether the antibodyblocked sperm—zona pellucida tight binding and/or spermpenetration into the ooplasm. The zona pellucida penetrationassay (ZPA) was also used to study the effects of four monoclonalantibodies (mAbs) on human sperm penetration into the zona pellucida.Seven mAbs against murine spermatozoa were tested for theirinhibitory effects on in-vitro fertilization (IVF) and HZA inmice. Of 22 patient sera with sperm immobilizing antibodies,21 (95.5%) inhibited HZA attachment and penetration, whereasthis did not occur in any of 13 patient sera without these antibodies.However, 19 of 22 (86.4%) patient sera with sperm immobilizingantibodies and eight of 13 (61.5%) patient sera without theseantibodies inhibited the SPA. Two (2C6, 1G12) of four mAbs againsthuman spermatozoa showed strong inhibitory effects in all theassays (HZA, ZPA and SPA). One mAb (3B10) did not inhibit HZAbut blocked ZPA and SPA. Another mAb (H6-3C4) seemed to haveno inhibitory effects on fertilization. Two (Vx 5 and Vx 8)of seven mAbs against murine spermatozoa inhibited IVF in micebut did not block mouse HZA. These findings suggest that antispermantibodies block fertilization at specific stages. Some of themmay inhibit sperm capacitation and thus prevent all processesof fertilization that follow. Some other antibodies may notaffect capacitation and sperm binding to zona pellucida butinhibit the acrosome reaction, followed by the blocking of spermpenetration through zona pellucida and ooplasm.     

Human and murine B-cells recognize the HBeAg/beta (or HBe2) epitope as a linear determinant.

The complete amino acid (aa) sequence of the hepatitis B virus (HBV) core protein (HBcAg), deduced from the genome of the HBV ayw subtype, was synthesized as decapeptides with five overlapping aas. The peptides were tested for reactivity with monoclonal antibodies (mAbs) to the beta (or HBe2) epitope of hepatitis B e antigen (HBe/b mAbs; 57/8, 78/3, 141/158 and 141/207). Cross-competition between the mAbs with a mAb to the HBe/alpha epitope (or HBe1) and an anti-HBc mAb showed that all the HBe/b mAbs specifically inhibited human anti-HBe/b binding. Screening the HBc/e peptides showed that all anti-HBe/b mAbs recognized a peptide covering the residues 126-135. Three of the mAbs, 78/3, 141/152 and 141/207, had a less restricted reactivity than the other two, suggesting the recognition of the HBe/b as a discontinuous determinant. Fine mapping of the region aa 126-135 was performed by synthesizing decapeptides with nine overlapping aas, covering residues aa 121-140. All mAbs, except 78/3, reacted with the linear sequence TPPAYR, at residues 128-133. An additional set of peptides was synthesized, where the six aas within the epitope 128-133 were substituted in turn by the other 19 possible aas. By this approach, the essential aas for mAb 57/8 were found to be the sequence of PPA at residues 129-131, and for mAb 141/158 the sequence PP-Y, at residues 129, 130 and 132, respectively. Human recognition of the linear HBe/b epitope was investigated by using a peptide covering residues 121-140 (p 33). Thirty-one sera from chronic carriers of HBsAg, of which seven were positive for HBeAg and the remaining 24 for anti-HBe, were investigated. Of the sera with HBeAg, two had low levels of anti/-HBe/b in the p 33 assay. Out of the sera with anti-HBe, eight were positive in the p 33 EIA. Thus, murine monoclonals and human sera may recognize the HBe/b epitope as a linear determinant residing around aa 130.     

Structural studies of a wild rabbit immunoglobulin light chain constant region

The amino acid sequence of a wild rabbit light chain constant region of allotype b95 was nearly completely determined by manual and automated Edman degradation procedures. The comparison of the b95 primary structure with the other b allotypes reveals about 20% substitutions between b95 and b4, b5 and b6, and 36% between b95 and b9. The substitutions are clustered in parts of the chain in agreement with our sequence data for b5 and b6. The presence in b95 of the characteristic cysteine residue at position 170 and the tryptophane residue at position 147 is in agreement with the serological similarity of these various rabbit kappa light chains. The examination of the rate of amino acid substitutions between the b95 chains and the other b allotypes shows that b95 is closer to b4, b5 and b6 than to b9.     

Group B streptococcal long-chain reaction.

The streptococcal long-chain reaction was adapted for the measurement of type-specific antibodies to group B beta-hemolytic streptococci (GBBHS). Rabbit antisera incubated with homologous but not heterologous GBBHS produced chains that were 18 to 33 times longer than chains produced by normal rabbit sera. The long chains were easily apparent, in most instances, by scanning the slides. Human sera with mouse protective and opsonic activity against GBBHS serotype Ia produced chains that were always significantly longer than those produced by incubation in nonimmune human sera. Absorption of rabbit or human sera with homologous but not heterologous organisms inhibited the capacity to induce the formation of long chains. The long-chain assay is a simple, rapid, and reproducible test that could constitute a valuable tool for the rapid identification of anti-GBBHS antibodies.     

Organization and structure of wild rabbit kappa2 genes: implications for regulation of kappa expression

In domestic populations, the rabbit kappa light chains are known to be encoded by two loci which are unequally expressed. The kappa1 chains account for the majority of total serum kappa chains, and display an unusual complex polymorphism. In order to study the evolution and the putative correlations between the expression, the organization and the structure of the kappa genes, we analysed the kappa loci in wild rabbit populations. The kappa genes of b95, b97 and b98 allotypes are organized in two loci similar to that of domestic rabbits. The structure of the constant region of the kappa2 locus was determined from a wild rabbit which expresses b95 allotype kappa1 chains. The Ckappa2bas2 of b95 displays a single silent mutation when compared to Ckappa2bas2 associated with b4 and one amino acid change relative to Ckappa2bas1 chain. Therefore, in contrast to the kappa1 locus, the constant regions of the kappa2 locus display strong conservation during evolution. A model based on conformation of the kappa chains is discussed to explain the evolution and expression of the two kappa loci.     

Characterisation of a linear binding site for a monoclonal antibody to hepatitis B core antigen.

The complete amino acid (aa) sequence of the hepatitis B virus (HBV) core protein (HBcAg), ayw subtype, was synthesized as decapeptides with five overlapping aas. The peptides were tested for reactivity with monoclonal antibodies (mAbs) to HBcAg (35/312, 37/275, and 7/275). All the mAbs specifically inhibited human anti-HBc by cross competition in assays for anti-HBc and anti-HBe. The mAb 35/312 recognised a peptide covering residues 76-85 of the HBcAg sequence. The other two mAbs did not react specifically with any linear peptide, suggesting discontinuous epitopes for these mAbs. The linear sequence EDPASR at residues 77-82 was found to constitute the epitope for mAb 35/312 when fine mapping the binding site. The most essential aas for mAb 35/312 were found to be the DP at residues 79-80, when peptides were synthesized where the aas at 77-83, were substituted by the other 19 aas. Since the mAb 35/312 inhibits the binding of human anti-HBc positive sera, which are known to recognise an SDS labile epitope, the sequence 77-82 might be a part of a larger discontinuous epitope. Alternatively the mAb 35/312 blocks the binding of human anti-HBc by steric hindrance.     

Rabbit-mouse hybridomas secreting intact rabbit immunoglobulin

Rabbit-mouse hybridomas offer the potential for production of monoclonal rabbit antibodies by immortal cell lines. In previous studies, it was possible to produce and stabilize rabbit-mouse hybrid cells secreting either a rabbit heavy or light chain. These have been useful for structural characterization of the individual rabbit immunoglobulin polypeptides and for isolation of large amounts of immunoglobulin mRNA for molecular studies. For some studies, however, it would be useful to have intact rabbit immunoglobulin molecules comparable to the myeloma proteins available in the human and mouse. The availability of rapid, sensitive and specific assays for rabbit heavy and light chains and allotypes located on specific chains has now permitted the early identification of clones secreting intact rabbit immunoglobulin. Vigorous cloning efforts have resulted in isolation and partial stabilization of three such clones. The first, H105, secretes a product with a kappa light chain bearing the b6 allotype and a mu-chain bearing the a1 allotype. Biochemical and serologic analyses of the product show that it is secreted as a fully assembled IgM pentamer and that the rabbit heavy and light chains are covalently associated. No rabbit J-chain gene was detected in H105 by Southern blot analysis. The second hydridoma, H134, secretes a product with a mol. wt of 150 K, consisting of a b4 light chain and an a1 heavy chain. The third, H171, secretes an alb4 IgG with antibody specificity for group C streptococcal carbohydrate. An additional rabbit-mouse hybridoma, H89, have been produced which secretes a rabbit heavy chain lacking group a allotypic activity. The rabbit heavy chain, which is associated with a mouse light chain, has an N-terminal amino acid sequence identical to a2-positive molecules although thorough serologic analysis revealed no group a allotypic activity.     

The common idiotypic specificity of anti-a2 allotype antibodies: contribution of H and L chains to idiotype expression

Previously an idiotypic specificity common to anti-a2 allotype Ab from 15 rabbits was detected and characterized. The contribution of H and L chains to the expression of this common idiotypic specificity was determined. Two types of recombinant IgG were prepared: (1) H chains from anti-a2 Ab with L chains from normal a3b4 IgG. and (2) L chains from anti-a2 Ab with H chains from normal a3b4 IgG. By inhibition of binding radioimmunoassay, recombinant IgG having either H or L chains from anti-a2 did not inhibit the binding between anti-a2 Ab and anti-idiotype Ab. By direct binding radioimmunoassay, recombinant IgG of H chains from anti-a2 Ab with L chains from a3b4 IgG reacted with anti-idiotype Ab whereas recombinant IgG with H chains from normal a3b4 IgG and L chains from anti-a2 Ab did not react. These results indicate that the common idiotypic specificity of anti-a2 Ab is determined primarily by the H chain; however, the full expression of the common idiotypic specificity requires the interaction of both H and L chains from anti-a2 Ab.     

抗rhEPO单克隆抗体的制备及初步应用

目的 :研制抗人促红细胞生成素的特异性单克隆抗体 (mAb) ,对其生物学特性进行初步鉴定 ,并用于转基因羊乳中重组人促红细胞生成素 (rhEPO)的提纯。方法 :以自制的rhEPO粗品免疫BALB/c小鼠 ,制备抗rhEPO的mAb。以Westernblot和间接ELISA法 ,对所获mAb进行初步鉴定。以纯化的mAb同预活化的Sepharose 4B偶联 ,制得mAb亲和层析柱 ,并用于转基因羊乳中rhEPO的提纯。结果 :获得两株可分泌特异性抗rhEPO的mAb的杂交瘤细胞株 (1E7和 2E6 )。Ig亚类 (型 )的鉴定分别为IgG1和IgG2b ,轻链均为κ型。用Westernblot证实 ,获得的mAb可特异性地识别rhEPO。用自制的免疫亲和层析柱用于转基因羊乳中rhEPO的提纯 ,具有很好的吸附作用 ,回收率达 70 %。结论 :成功地获得两株可分泌特异性抗rhEPO的mAb的杂交瘤细胞。用自制的免疫亲和层析柱提纯转基因羊奶中的rhEPO具有较高的吸附效率     

Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics

Following CD4 receptor binding to the HIV-1 envelope spike (Env), the conserved N-heptad repeat (NHR) region of gp41 forms a coiled-coil that is a precursor to the fusion reaction. Although it has been a target of drug and vaccine design, there are few monoclonal antibody (mAb) tools with which to probe the antigenicity and immunogenicity specifically of the NHR coiled-coil. Here, we have rescued HIV-1-neutralizing anti-NHR mAbs from immune phage display libraries that were prepared (i) from b9 rabbits immunized with a previously described mimetic of the NHR coiled-coil, N35(CCG)-N13, and (ii) from an HIV-1 infected individual. We describe a rabbit single-chain Fv fragment (scFv), 8K8, and a human Fab, DN9, which specifically recognize NHR coiled-coils that are unoccupied by peptide corresponding to the C-heptad repeat or CHR region of gp41 (e.g. C34). The epitopes of 8K8 and DN9 were found to partially overlap with that of a previously described anti-NHR mAb, IgG D5; however, 8K8 and DN9 were much more specific than D5 for unoccupied NHR trimers. The mAbs, including a whole IgG 8K8 molecule, neutralized primary HIV-1 of clades B and C in a pseudotyped virus assay with comparable, albeit relatively modest potency. Finally, a human Fab T3 and a rabbit serum (both non-neutralizing) were able to block binding of D5 and 8K8 to a gp41 NHR mimetic, respectively, but not the neutralizing activity of these mAbs. We conclude from these results that NHR coiled-coil analogs of HIV-1 gp41 elicit many Abs during natural infection and through immunization, but that due to limited accessibility to the corresponding region on fusogenic gp41 few can neutralize. Caution is therefore required in targeting the NHR for vaccine design. Nevertheless, the mAb panel may be useful as tools for elucidating access restrictions to the NHR of gp41 and in designing potential improvements to mimetics of receptor-activated Env.